# Study of YOLT-203 in Children and Adults With Primary Hyperoxaluria Type 1 (PH1)

Clinical trial · YolTech Therapeutics Co., Ltd

- Archive id: nct:NCT07587021
- Published: 2026-05-14
- Venue: ClinicalTrials.gov
- ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT07587021
- Source URL: https://clinicaltrials.gov/study/NCT07587021
- Provenance: clinicaltrials

## Abstract

This study will be conducted to evaluate the efficacy and safety of YOLT-203 in children and adults with Primary Hyperoxaluria Type 1. After the initial randomized, 6-month double-blind, placebo-controlled period, participants who were initially assigned to placebo will receive a single-dose of YOLT-203 treatment whereas participants in the YOLT-203 group will receive a single-dose of placebo infusion. For patients interested in additional information on how to participate, please follow this link: https://mytomorro.ws/ph1trial.

_Abstract reproduced under ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters._

## Trial details

- status: RECRUITING
- phase: PHASE2
- study type: INTERVENTIONAL
- enrollment: 36
- sponsor: YolTech Therapeutics Co., Ltd
- conditions: Primary Hyperoxaluria Type 1; PH1
- interventions: GENETIC: YOLT-203; DRUG: Placebo
- start date: 2026-09-16
- start date type: ACTUAL
- primary completion date: 2027-08-01
- has results: false
- data source: ClinicalTrials.gov
- data processed: 2026-10-29T09:00:05
- modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters

Topics: [CRISPR & Gene-Editing Therapies](https://space-kitty.com/topics/gene-editing-therapies)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.